Can YKL-40 be used as a biomarker for interstitial lung disease?: A systematic review and meta-analysis.
Biomarkers
/ metabolism
Bronchoalveolar Lavage Fluid
/ chemistry
Case-Control Studies
Chitinase-3-Like Protein 1
/ metabolism
Female
Humans
Idiopathic Pulmonary Fibrosis
/ metabolism
Lung
/ physiopathology
Lung Diseases, Interstitial
/ metabolism
Male
Middle Aged
Prognosis
Pulmonary Alveolar Proteinosis
/ metabolism
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
30 Apr 2021
30 Apr 2021
Historique:
received:
13
05
2020
accepted:
31
03
2021
entrez:
28
4
2021
pubmed:
29
4
2021
medline:
5
5
2021
Statut:
ppublish
Résumé
Interstitial lung disease (ILD) has a poor prognosis and lacks specific biomarkers for early diagnosis, assessment of disease severity, and prognosis. YKL-40 levels were found to be elevated in patients with ILD, but these results are inconsistent. Therefore, we conducted a systematic review and meta-analysis to accurately study the relation between YKL-40 and ILD. We performed a systematic literature search in many databases (PubMed, Embase, the China National Knowledge Infrastructure, and Wanfang databases) and commercial Internet search engines to identify studies involving the role of YKL-40 in patients with ILD. The weighted mean difference with its 95% confidence interval were used to investigate the effect sizes. If obvious heterogeneity was found in the meta-analysis, the level of YKL-40 was directly compared by the Mann-Whitney test. Sixteen eligible articles were finally identified. The results showed that the serum YKL-40 levels of patients with idiopathic pulmonary fibrosis, connective tissue-related ILD, sarcoidosis, cryptogenic tissue pneumonia, asbestosis-ILD, and idiopathic nonspecific interstitial pneumonia were higher than those in controls, but there was no increase in patients with pulmonary alveolar proteinosis. We also found that there are certain differences in the serum YKL-40 levels in patients with different types of ILD. The results showed that the bronchoalveolar lavage fluid YKL-40 levels of patients with idiopathic pulmonary fibrosis were significantly higher than that in controls. A systematic review indicated that there were correlations between the serum YKL-40 levels and lung function in patients with different ILD. In addition, YKL-40 may be used as a valuable biomarker for survival, with risk ratios ranging from 1.006 to 10.9. This study suggests that YKL-40 may be a useful biomarker for the diagnosis and prognosis of ILD.
Sections du résumé
BACKGROUND
BACKGROUND
Interstitial lung disease (ILD) has a poor prognosis and lacks specific biomarkers for early diagnosis, assessment of disease severity, and prognosis. YKL-40 levels were found to be elevated in patients with ILD, but these results are inconsistent. Therefore, we conducted a systematic review and meta-analysis to accurately study the relation between YKL-40 and ILD.
METHODS
METHODS
We performed a systematic literature search in many databases (PubMed, Embase, the China National Knowledge Infrastructure, and Wanfang databases) and commercial Internet search engines to identify studies involving the role of YKL-40 in patients with ILD. The weighted mean difference with its 95% confidence interval were used to investigate the effect sizes. If obvious heterogeneity was found in the meta-analysis, the level of YKL-40 was directly compared by the Mann-Whitney test.
RESULTS
RESULTS
Sixteen eligible articles were finally identified. The results showed that the serum YKL-40 levels of patients with idiopathic pulmonary fibrosis, connective tissue-related ILD, sarcoidosis, cryptogenic tissue pneumonia, asbestosis-ILD, and idiopathic nonspecific interstitial pneumonia were higher than those in controls, but there was no increase in patients with pulmonary alveolar proteinosis. We also found that there are certain differences in the serum YKL-40 levels in patients with different types of ILD. The results showed that the bronchoalveolar lavage fluid YKL-40 levels of patients with idiopathic pulmonary fibrosis were significantly higher than that in controls. A systematic review indicated that there were correlations between the serum YKL-40 levels and lung function in patients with different ILD. In addition, YKL-40 may be used as a valuable biomarker for survival, with risk ratios ranging from 1.006 to 10.9.
CONCLUSIONS
CONCLUSIONS
This study suggests that YKL-40 may be a useful biomarker for the diagnosis and prognosis of ILD.
Identifiants
pubmed: 33907118
doi: 10.1097/MD.0000000000025631
pii: 00005792-202104300-00033
pmc: PMC8083999
doi:
Substances chimiques
Biomarkers
0
CHI3L1 protein, human
0
Chitinase-3-Like Protein 1
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e25631Subventions
Organisme : National Key R&D Program of China
ID : 2017YFC1309703
Organisme : Project funded by China Postdoctoral Science Foundation
ID : 2020M673259
Organisme : Post-Doctor Research Project, West China Hospital, Sichuan University
ID : 2020HXBH013
Informations de copyright
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
Mikolasch TA, Garthwaite HS, Porter JC. Update in diagnosis and management of interstitial lung disease. Clin Med (London, England) 2016;16: (Suppl 6): s71–8.
Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013;188:733–48.
Park SW, Baek AR, Lee HL, et al. Korean guidelines for diagnosis and management of interstitial lung diseases: Part 1. introduction. Tubercul Respir Dis 2019;82:269–76.
Rivera-Ortega P, Molina-Molina M. Interstitial lung diseases in developing countries. Ann Global Health 2019;85:04.
Giacomelli R, Liakouli V, Berardicurti O, et al. Interstitial lung disease in systemic sclerosis: current and future treatment. Rheumatol Int 2017;37:853–63.
Vancheri C, Failla M, Crimi N, et al. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J 2010;35:496–504.
Collard HR, Ward AJ, Lanes S, et al. Burden of illness in idiopathic pulmonary fibrosis. J Med Econ 2012;15:829–35.
Alqalyoobi S, Adegunsoye A, Linderholm A, et al. Circulating plasma biomarkers of progressive interstitial lung disease. Am J Respir and Critical Care Medicine 2020;201:250–3.
Mathai SC, Danoff SK. Management of interstitial lung disease associated with connective tissue disease. BMJ (Clin Res Ed) 2016;352:h6819.
Rehli M, Krause SW, Andreesen R. Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics 1997;43:221–5.
Duru S, Yuceege M, Ardic S. Chitinases and lung diseases. Tuberk Toraks 2013;61:71–5.
Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Danish Med Bull 2006;53:172–209.
Nishikawa KC, Millis AJ. gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells. Exp Cell Res 2003;287:79–87.
Furuhashi K, Suda T, Nakamura Y, et al. Increased expression of YKL-40, a chitinase-like protein, in serum and lung of patients with idiopathic pulmonary fibrosis. Respir Med 2010;104:1204–10.
Johansen JS, Milman N, Hansen M, et al. Increased serum YKL-40 in patients with pulmonary sarcoidosis--a potential marker of disease activity? Respir Med 2005;99:396–402.
Korthagen NM, van Moorsel CH, Barlo NP, et al. Serum and BALF YKL-40 levels are predictors of survival in idiopathic pulmonary fibrosis. Respir Med 2011;105:106–13.
Tong X, Wang D, Liu S, et al. The YKL-40 protein is a potential biomarker for COPD: a meta-analysis and systematic review. Int J Chronic Obstr Pulmon Dis 2018;13:409–18.
Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014;14:135.
Borenstein M, Hedges L, Rothstein H. Meta-analysis: fixed effect vs. random effects. Meta-analysis com. 2007 (access date September 21, 2019).
Korthagen NM, van Moorsel CH, Zanen P, et al. Evaluation of circulating YKL-40 levels in idiopathic interstitial pneumonias. Lung 2014;192:975–80.
Jiang L, Wang Y, Peng Q, et al. Serum YKL-40 level is associated with severity of interstitial lung disease and poor prognosis in dermatomyositis with anti-MDA5 antibody. Clin Rheumatol 2019;38:1655–63.
Long X, He X, Ohshimo S, et al. Serum YKL-40 as predictor of outcome in hypersensitivity pneumonitis. Eur Respir J 2017;49:1501924.
Hozumi H, Fujisawa T, Enomoto N, et al. Clinical Utility of YKL-40 in Polymyositis/dermatomyositis-associated Interstitial Lung Disease. J Rheumatol 2017;44:1394–401.
Vaananen T, Lehtimaki L, Vuolteenaho K, et al. Glycoprotein YKL-40 levels in plasma are associated with fibrotic changes on HRCT in asbestos-exposed subjects. Mediat Inflamm 2017;2017:1797512.
Furukawa T, Matsui K, Kitano M, et al. Relationship between YKL-40 and pulmonary arterial hypertension in systemic sclerosis. Mod Rheumatol 2019;29:476–83.
Bonella F, Long X, He X, et al. Serum YKL-40 is a reliable biomarker for pulmonary alveolar proteinosis. Respirology 2017;22:1371–8.
Nordenbaek C, Johansen JS, Halberg P, et al. High serum levels of YKL-40 in patients with systemic sclerosis are associated with pulmonary involvement. Scand J Rheumatol 2005;34:293–7.
Chen S, Zhou F. Corralation betwwen serum YKL-40 and polymyositis/dermatomyositis. J Clin Pathol Res (In Chinese) 2019;39:947–51.
Li Y, Tian X, Gui Y, et al. Serum markers in patients with idiopathic pulmonary alveolar proteinosis. Chin J Tubere Respir Dis (In Chinese) 2014;37:497–501.
Corradi M, Goldoni M, Alinovi R, et al. YKL-40 and mesothelin in the blood of patients with malignant mesothelioma, lung cancer and asbestosis. Anticancer Res 2013;33:5517–24.
Gao MZ, Wei YY, Xu QW, et al. Elevated serum YKL-40 correlates with clinical characteristics in patients with polymyositis or dermatomyositis. Ann Clin Biochem 2019;56:95–9.
Kruit A, Grutters JC, Ruven HJ, et al. A CHI3L1 gene polymorphism is associated with serum levels of YKL-40, a novel sarcoidosis marker. Respir Med 2007;101:1563–71.
Gratchev A, Schmuttermaier C, Mamidi S, et al. Expression of osteoarthritis marker YKL-39 is stimulated by transforming growth factor beta (TGF-beta) and IL-4 in differentiating macrophages. Biomark Insights 2008;3:39–44.
Recklies AD, Ling H, White C, et al. Inflammatory cytokines induce production of CHI3L1 by articular chondrocytes. J Biol Chem 2005;280:41213–21.
Zhu Z, Zheng T, Homer RJ, et al. Acidic mammalian chitinase in asthmatic Th2 inflammation and IL-13 pathway activation. Science 2004;304:1678–82.
Lee CG, Hartl D, Lee GR, et al. Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis. J Exp Med 2009;206:1149–66.
Lee CG, Da Silva CA, Dela Cruz CS, et al. Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. Ann Rev Physiol 2011;73:479–501.
Horowitz JC, Rogers DS, Sharma V, et al. Combinatorial activation of FAK and AKT by transforming growth factor-beta1 confers an anoikis-resistant phenotype to myofibroblasts. Cell signal 2007;19:761–71.
Shao R, Hamel K, Petersen L, et al. YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene 2009;28:4456–68.